BLFS vs. ZYXI, AXGN, EDAP, SLNO, OM, INMD, CNMD, TMDX, LIVN, and RLAY
Should you be buying BioLife Solutions stock or one of its competitors? The main competitors of BioLife Solutions include Zynex (ZYXI), AxoGen (AXGN), Edap Tms (EDAP), Soleno Therapeutics (SLNO), Outset Medical (OM), InMode (INMD), CONMED (CNMD), TransMedics Group (TMDX), LivaNova (LIVN), and Relay Therapeutics (RLAY). These companies are all part of the "medical" sector.
Zynex (NASDAQ:ZYXI) and BioLife Solutions (NASDAQ:BLFS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation, dividends and community ranking.
Zynex has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500.
Zynex has higher revenue and earnings than BioLife Solutions. BioLife Solutions is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.
Zynex has a net margin of 5.28% compared to Zynex's net margin of -46.37%. BioLife Solutions' return on equity of 16.82% beat Zynex's return on equity.
29.7% of Zynex shares are owned by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are owned by institutional investors. 52.1% of Zynex shares are owned by insiders. Comparatively, 2.7% of BioLife Solutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
BioLife Solutions received 279 more outperform votes than Zynex when rated by MarketBeat users. Likewise, 66.82% of users gave BioLife Solutions an outperform vote while only 50.00% of users gave Zynex an outperform vote.
Zynex currently has a consensus target price of $18.00, indicating a potential upside of 60.57%. BioLife Solutions has a consensus target price of $23.40, indicating a potential upside of 33.49%. Given BioLife Solutions' higher probable upside, equities research analysts plainly believe Zynex is more favorable than BioLife Solutions.
In the previous week, BioLife Solutions had 11 more articles in the media than Zynex. MarketBeat recorded 12 mentions for BioLife Solutions and 1 mentions for Zynex. Zynex's average media sentiment score of 0.36 beat BioLife Solutions' score of 0.07 indicating that BioLife Solutions is being referred to more favorably in the news media.
Summary
Zynex beats BioLife Solutions on 9 of the 17 factors compared between the two stocks.
Get BioLife Solutions News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLFS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioLife Solutions Competitors List
Related Companies and Tools
